Key result
A multidisciplinary approach to GLP-1 receptor agonists and SGLT2 inhibitors marks a new era in cardiometabolic care for patients with diabetes and heart disease.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lucà et al. (2025) studied this question. A multidisciplinary approach to GLP-1 receptor agonists and SGLT2 inhibitors marks a new era in cardiometabolic care for patients with diabetes and heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: